Pre-transjugular-intrahepatic-portosystemic-shunt measurement of hepatic venous pressure gradient and its clinical application: A comparison study

被引:0
|
作者
Xi-Xuan Wang [1 ,2 ]
Xiao-Chun Yin [1 ]
Li-Hong Gu [1 ]
Hui-Wen Guo [3 ]
Yang Cheng [1 ]
Yan Liu [1 ]
Jiang-Qiang Xiao [1 ]
Yi Wang [1 ]
Wei Zhang [1 ]
Xiao-Ping Zou [1 ]
Lei Wang [1 ]
Ming Zhang [1 ]
Yu-Zheng Zhu-Ge [1 ,2 ]
Feng Zhang [1 ]
机构
[1] Department of Gastroenterology,Affiliated Drum Tower Hospital of Nanjing University Medical School
[2] Medical School,Southeast University
[3] Department of Gastroenterology,The Affiliated Jiangning Hospital of Nanjing Medical University
基金
中国国家自然科学基金;
关键词
D O I
暂无
中图分类号
R575 [肝及胆疾病];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND It is controversial whether transjugular intrahepatic portosystemic shunt(TIPS) placement can improve long-term survival.AIM To assess whether TIPS placement improves survival in patients with hepaticvenous-pressure-gradient(HVPG) ≥ 16 mm Hg, based on HVPG-related risk stratification.METHODS Consecutive variceal bleeding patients treated with endoscopic therapy + nonselective β-blockers(NSBBs) or covered TIPS placement were retrospectively enrolled between January 2013 and December 2019. HVPG measurements were performed before therapy. The primary outcome was transplant-free survival; secondary endpoints were rebleeding and overt hepatic ence-phalopathy(OHE).RESULTS A total of 184 patients were analyzed(mean age, 55.27 years ± 13.86, 107 males; 102 in the EVL+NSBB group, 82 in the covered TIPS group). Based on the HVPG-guided risk stratification, 70 patients had HVPG < 16 mm Hg, and 114 patients had HVPG ≥ 16 mm Hg. The median follow-up time of the cohort was 49.5 mo. There was no significant difference in transplant-free survival between the two treatment groups overall(hazard ratio [HR], 0.61; 95% confidence interval [CI]: 0.35-1.05; P = 0.07). In the high-HVPG tier, transplant-free survival was higher in the TIPS group(HR, 0.44; 95%CI: 0.23-0.85; P = 0.004). In the low-HVPG tier, transplantfree survival after the two treatments was similar(HR, 0.86; 95%CI: 0.33-0.23; P = 0.74). Covered TIPS placement decreased the rate of rebleeding independent of the HVPG tier(P < 0.001). The difference in OHE between the two groups was not statistically significant(P = 0.09; P = 0.48).CONCLUSION TIPS placement can effectively improve transplant-free survival when the HVPG is greater than 16 mm Hg.
引用
收藏
页码:3519 / 3533
页数:15
相关论文
共 50 条
  • [21] Clinical experience of transjugular intrahepatic portosystemic shunt (TIPS) and its effects on systemic hemodynamics
    Naritaka, Y
    Ogawa, K
    Shimakawa, T
    Wagatsuma, Y
    Konno, S
    Katsube, T
    Hamaguchi, K
    Hosokawa, T
    HEPATO-GASTROENTEROLOGY, 2004, 51 (59) : 1470 - 1472
  • [22] Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis:: Clinical, laboratory, psychometric, and electroencephalographic investigations
    Nolte, W
    Wiltfang, J
    Schindler, C
    Münke, H
    Unterberg, K
    Zumhasch, U
    Figulla, HR
    Werner, G
    Hartmann, H
    Ramadori, G
    HEPATOLOGY, 1998, 28 (05) : 1215 - 1225
  • [23] Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study
    Riggio, O
    Masini, A
    Efrati, C
    Nicolao, F
    Angeloni, S
    Salvatori, FM
    Bezzi, M
    Attili, AF
    Merli, M
    JOURNAL OF HEPATOLOGY, 2005, 42 (05) : 674 - 679
  • [24] Prediction of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt treatment: a cohort study
    Yang Yang
    Sirui Fu
    Bin Cao
    Kenan Hao
    Yong Li
    Jianwen Huang
    Wenfeng Shi
    Chongyang Duan
    Xiao Bai
    Kai Tang
    Shirui Yang
    Xiaofeng He
    Ligong Lu
    Hepatology International, 2021, 15 : 730 - 740
  • [25] Prediction of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt treatment: a cohort study
    Yang, Yang
    Fu, Sirui
    Cao, Bin
    Hao, Kenan
    Li, Yong
    Huang, Jianwen
    Shi, Wenfeng
    Duan, Chongyang
    Bai, Xiao
    Tang, Kai
    Yang, Shirui
    He, Xiaofeng
    Lu, Ligong
    HEPATOLOGY INTERNATIONAL, 2021, 15 (03) : 730 - 740
  • [26] No difference in portal and hepatic venous bacterial DNA in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt insertion
    Mortensen, Christian
    Karlsen, Stine
    Gronbaek, Henning
    Nielsen, Dennis T.
    Frevert, Susanne
    Clemmesen, Jens O.
    Moller, Soren
    Jensen, Jorgen S.
    Bendtsen, Flemming
    LIVER INTERNATIONAL, 2013, 33 (09) : 1309 - 1315
  • [27] Correlation between portal/hepatic vein gradient and response to transjugular intrahepatic portosystemic shunt creation in refractory ascites
    Nair, S
    Singh, R
    Yoselewitz, M
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2004, 15 (12) : 1431 - 1434
  • [28] Comparison of clinical outcomes of transjugular intrahepatic portosystemic shunt for refractory ascites and recurrent nonrefractory ascites
    Luo, Shi-Hua
    Zhang, Hui-Fang
    Liu, Wei
    Chu, Jian-Guo
    Chen, Jian-Yong
    WORLD JOURNAL OF HEPATOLOGY, 2025, 17 (02)
  • [29] Retrospective Analysis of Venograms of Hepatic and Portal Veins: Clinical Implications for Transjugular Intrahepatic Portosystemic Shunt Placement
    Qin, Jianping
    Tang, Shanhong
    He, Qianwen
    Tang, Wen
    Yao, Xin
    Jiang, Mingde
    Sheng, Jingping
    Zeng, Weizheng
    Gu, Ming
    HEPATO-GASTROENTEROLOGY, 2014, 61 (133) : 1165 - 1169
  • [30] Endoscopic therapy plus β-blocker vs. covered transjugular intrahepatic portosystemic shunt for prevention of variceal rebleeding in cirrhotic patients with hepatic venous pressure gradient ≥16 mmHg
    Guo, Huiwen
    Zhang, Feng
    Yin, Xiaochun
    Zhang, Ming
    Xiao, Jiangqiang
    Wang, Yi
    Zhang, Bin
    Zhang, Wei
    Zou, Xiaoping
    Zhuge, Yuzheng
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 (11) : 1427 - 1435